Arcturus TherapeuticsARCT
ARCT
About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Employees: 176
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
181% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $1.26M
0.33% less ownership
Funds ownership: 98.39% [Q4 2024] → 98.06% (-0.33%) [Q1 2025]
3% less funds holding
Funds holding: 147 [Q4 2024] → 143 (-4) [Q1 2025]
10% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 50
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
38% less capital invested
Capital invested by funds: $453M [Q4 2024] → $283M (-$170M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
158%
upside
Avg. target
$51
310%
upside
High target
$66
433%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Greg Harrison | 158%upside $32 | Sector Outperform Initiated | 28 May 2025 |
Wells Fargo Yanan Zhu | 263%upside $45 | Overweight Maintained | 14 May 2025 |
Canaccord Genuity Whitney Ijem | 433%upside $66 | Buy Maintained | 13 May 2025 |
HC Wainwright & Co. Ed Arce | 385%upside $60 | Buy Reiterated | 10 Apr 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
2 weeks ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Jefferies Global Healthcare Conference (Presentation) Wednesday, June 4, 2025 (4:20 p.m. ET) Goldman Sachs Annual Global Healthcare Confere.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
1 month ago
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations and Marketing Joe Payne - President and Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Partners Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Jake Roberge - William Blair Whitney Ijem - Canaccord Genuity Samantha Schaeffer - Cantor Fitzgerald Tom Shrader - BTIG Yigal Nochomovitz - Citi Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day. I would like to welcome everyone to Arcturus Therapeutics' First Quarter 2025 Earnings Call.
Negative
Zacks Investment Research
1 month ago
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.
Neutral
Business Wire
1 month ago
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. “We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to p.
Negative
Zacks Investment Research
1 month ago
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.
Neutral
Zacks Investment Research
2 months ago
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
Neutral
Business Wire
2 months ago
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease.
Charts implemented using Lightweight Charts™